PMC

(a) Systolic blood pressure was increased in the idazoxan arm [F_2,16=7.96; p<.05]. (b) There were no effects of alcohol or 40-mg of idazoxan on diastolic blood pressure. (c) Alcohol increased pulse rate from baseline in both groups, whether pretreated with 40-mg of idazoxan or placebo, [F_2,16=12.22; p<.001].

Effects of idazoxan alone or co-administered with agomelatine, gabapentin or ‘agomelatine + gabapentin’ on mechanical allodynia in CCI-SN (A) and CCI-ION (B) rats. Left panels: Idazoxan (2 mg/kg i.p.) or its vehicle (saline) was administered 30 min before other treatments in rats whose right SN (A) or ION (B) had been ligated 2 weeks before. Five different treatment groups were made: (1) idazoxan + HEC + saline, (2) idazoxan + agomelatine (45 mg/kg) + saline, (3) idazoxan + HEC + gabapentin (50 mg/kg), (4) agomelatine + gabapentin, (5) idazoxan + agomelatine + gabapentin. Pressure threshold values (as g) were determined as described in the legend to Figure . Each point is the mean ± SEM of independent determinations in n rats for each condition. ^∗P < 0.05, compared with pressure threshold values determined just prior to treatments (0 on abscissa), one way ANOVA with repeated measures, Dunnett’s test. C on abscissa: intact healthy rats before surgery. In both CCI-SN (A) and CCI-ION (B) rats, ‘saline+HEC’-treated groups were also included, but, for the sake of clarity, corresponding data are not represented as they superimposed with those obtained in rats treated with idazoxan + HEC + saline. Right panels: AUC values calculated from the respective time-course curves: (1) idazoxan + HEC + saline [n = 7 (A), n = 5 (B)]; (2) idazoxan + agomelatine + saline (n = 6/6); (3) idazoxan + HEC + gabapentin (n = 6/5); (4) agomelatine + gabapentin (n = 7/6); 5 = idazoxan + agomelatine + gabapentin (n = 7/14). A- CCI-SN : one way ANOVA [F(4,28) = 16.33, P < 0.0001] followed by Tukey’s test (^∗∗P < 0.01, ^∗∗∗P < 0.001); B- CCI-ION : one way ANOVA [F(4,35) = 8.267, P < 0.0001] followed by Tukey’s test (^∗P < 0.05, ^∗∗P < 0.01, ^∗∗∗P < 0.001).

Participants showed an increase in the (a) anesthesia [F_2,16=9.12; p<.05], (b) impairment [F_2,16=13.75; p<.001], (c) warm [F_2,16=32.92; p<.05] and, (d) central [F_2,16=7.18; p<.01] subscales time effect of alcohol. None of the subscales showed significant effects [p>.05] due to idazoxan dose, or a time by idazoxan dose interaction.

Participants receiving 40-mg of idazoxan reported: (a) a decrease in the stimulant subscale [t₉=2.48; p<.05] on the ascending limb of the BrAC curve and (b) an increase in the sedative subscale [t₉=2.18; p<.05] on the ascending limb of the BrAC curve compared to placebo.